

Marketplace SB 1742 June/ August 2025

Drug/Class	Effective Date	Overview
Inzirqo	6/1/2025	Adding to formulary with PA (PA required for members age 9 years and older)
Tremfya	6/1/2025	Adding Crohn's disease (CD) indication
Rivfloza	6/1/2025	Removing age minimum from PA criteria due to age expansion review
Entyvio SC	8/1/2025	Removing "or in consultation with" for prescriber requirement for ulcerative colitis (UC) and Crohn's disease (CD) criteria; Adding Tremfya as step option for CD
Tazverik	6/1/2025	Removing documentation requirement for <i>EZH2</i> mutation
Lytgobi	6/1/2025	Removing documentation requirement for oncology mutation
Rubraca	6/1/2025	Removing documentation requirement for <i>BRCA</i> mutated prostate cancer
Cimzia	8/1/2025	Adding Tremfya option for Crohn's disease (CD)